Esther Need
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Esther Need has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Shreya Goel
Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA
3 shared publications - Sixiang Shi
Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA
3 shared publications Ayden Berndt
Department of Biomedical Engineering, University of Utah, Salt Lake City, UT 84112, USA
2 shared publicationsMatthew Goff
Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA
2 shared publicationsNeetu Singh
Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112
2 shared publicationsAlex Shelton
School of Biological Science, University of Utah, Salt Lake City, UT 84112
1 shared publication
Latest Publications
- Open Access
- 26 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (26) , eaef0121
FOLR1-targeted actinium-225–based alpha-particle therapy eliminates ovarian cancer
Despite the advancement in therapies, ovarian cancer treatment is challenging because of poor prognosis and high relapse associated with acquired resistance. Emerging targeted alpha particles, particularly actinium-225 ( 225 Ac), for treating refractory cancers have opened avenues for improved therapeutic options. Here, we describe a successful example of folate receptor 1 (FOLR1)–targeted 225 Ac alpha-particle therapy for treatment of ovarian cancer. Longitudinal positron emission tomography imaging demonstrated high tumor-specific uptake of αFOLR1 (anti-FOLR1 antibody) in SKOV3 xenografts. FOLR1-targeted 225 Ac demonstrated high therapeutic efficacy, achieving marked tumor regression, 80% survival, and 40% complete tumor elimination. The therapy resulted in tumor-specific double-stranded DNA damage, and no obvious toxicity was observed in normal tissues. Estimated human dosimetry showed high absorbed dose for tumor and minimal absorbed dose for healthy tissues, establishing its safety. In totality, FOLR1-targeted 225 Ac alpha-particle therapy is an efficacious and safe treatment with high feasibility for clinical translation to fight against ovarian cancer.
- 26 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (26) , eaef0121
Open AccessFOLR1-targeted actinium-225–based alpha-particle therapy eliminates ovarian cancer
Despite the advancement in therapies, ovarian cancer treatment is challenging because of poor prognosis and high relapse associated with acquired resistance. Emerging targeted alpha particles, particularly actinium-225 ( 225 Ac), for treating refractory cancers have opened avenues for improved therapeutic options. Here, we describe a successful example of folate receptor 1 (FOLR1)–targeted 225 Ac alpha-particle therapy for treatment of ovarian cancer. Longitudinal positron emission tomography imaging demonstrated high tumor-specific uptake of αFOLR1 (anti-FOLR1 antibody) in SKOV3 xenografts. FOLR1-targeted 225 Ac demonstrated high therapeutic efficacy, achieving marked tumor regression, 80% survival, and 40% complete tumor elimination. The therapy resulted in tumor-specific double-stranded DNA damage, and no obvious toxicity was observed in normal tissues. Estimated human dosimetry showed high absorbed dose for tumor and minimal absorbed dose for healthy tissues, establishing its safety. In totality, FOLR1-targeted 225 Ac alpha-particle therapy is an efficacious and safe treatment with high feasibility for clinical translation to fight against ovarian cancer.
- Open Access
- 6 June 2026
- Published by Elsevier in SSRN Electronic Journal
Cardiomyocytes Drive [18F]-FDG Uptake in Arrhythmogenic Cardiomyopathy
Background: Arrhythmogenic cardiomyopathy (ACM) is a heritable cardiac disease characterized by arrhythmias, progressive myocardial injury, and sudden death. Inflammation is central to disease progression. 2-deoxy-2-[18F]-Fluoroglucose positron emission tomography ([18F]FDG PET) is increasingly used to identify glycolytically active immune cells in inflammatory cardiomyopathies. However, whether [18F]FDG uptake in ACM reflects myocardial immune cell recruitment remains unclear. Methods and Results: We performed cardiac [18F]FDG PET imaging in wild-type and desmoglein-2 (DSG2) mutant mice, a well established model of ACM, followed by immune cell profiling using flow cytometry. DSG2 mutant mice exhibited significantly increased cardiac [18F]FDG uptake compared with wild type controls. Although both CCR2+ and CCR2- macrophage populations correlated with the [18F]FDG uptake, pharmacologic depletion of macrophages with liposomal clodronate did not reduce [18F]FDG uptake. High resolution confocal microscopy using the fluorescent glucose analog 2-NBDG demonstrated increased uptake localized predominantly to cardiomyocytes in DSG2 mutant hearts.Conclusions: Myocardial [18F]FDG uptake is not dependent on macrophage abundance and is predominantly localized to cardiomyocytes. These findings suggest that [18F]FDG uptake reflects cardiomyocyte metabolic remodeling driven by cell-intrinsic inflammatory signaling pathways, rather than serving as a direct marker of immune cell infiltration.
- 6 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessCardiomyocytes Drive [18F]-FDG Uptake in Arrhythmogenic Cardiomyopathy
Background: Arrhythmogenic cardiomyopathy (ACM) is a heritable cardiac disease characterized by arrhythmias, progressive myocardial injury, and sudden death. Inflammation is central to disease progression. 2-deoxy-2-[18F]-Fluoroglucose positron emission tomography ([18F]FDG PET) is increasingly used to identify glycolytically active immune cells in inflammatory cardiomyopathies. However, whether [18F]FDG uptake in ACM reflects myocardial immune cell recruitment remains unclear. Methods and Results: We performed cardiac [18F]FDG PET imaging in wild-type and desmoglein-2 (DSG2) mutant mice, a well established model of ACM, followed by immune cell profiling using flow cytometry. DSG2 mutant mice exhibited significantly increased cardiac [18F]FDG uptake compared with wild type controls. Although both CCR2+ and CCR2- macrophage populations correlated with the [18F]FDG uptake, pharmacologic depletion of macrophages with liposomal clodronate did not reduce [18F]FDG uptake. High resolution confocal microscopy using the fluorescent glucose analog 2-NBDG demonstrated increased uptake localized predominantly to cardiomyocytes in DSG2 mutant hearts.Conclusions: Myocardial [18F]FDG uptake is not dependent on macrophage abundance and is predominantly localized to cardiomyocytes. These findings suggest that [18F]FDG uptake reflects cardiomyocyte metabolic remodeling driven by cell-intrinsic inflammatory signaling pathways, rather than serving as a direct marker of immune cell infiltration.
- Open Access
Positron Emission Tomography of CD47/SIRPα Axis and Image-Informed Therapeutic Design
CD47/SIRPα immune axis is of substantial clinical interest for innate cancer immunotherapy. Development on this axis has largely focused on monoclonal antibody agents and combination therapy strategies. Clinical use is challenging due to dose limiting side effects and severe anemia. Better understanding of the whole-body dynamics of CD47/SIRPα can be used to improve the developmental and therapeutic strategies targeting this axis. Herein, we developed anti-CD47 and anti-SIRPα radiotracers with good yields and stability. CD47/SIRPα biodistribution showed consistent whole-body results in healthy and colorectal cancer (CT26) allograft mice, demonstrating significant uptake in normal organs liver and spleen in addition to tumor accumulation of these agents. Enhancing immunogenicity via low-dose radiotherapy had no impact on over-all biodistribution but caused small, significant changes for anti-SIRPα tumor uptake. Antibody PEGylation of the anti-SIRPα tracer was further able to modify the whole-body distribution and reduce splenic uptake. These findings suggest that SIRPα targeted agents may benefit from co-therapies and drug delivery systems to optimize tumor uptake. Our work highlights the importance of in vivo molecular imaging in addition to in vitro and ex vivo assays when evaluating therapeutic designs.
Open AccessPositron Emission Tomography of CD47/SIRPα Axis and Image-Informed Therapeutic Design
CD47/SIRPα immune axis is of substantial clinical interest for innate cancer immunotherapy. Development on this axis has largely focused on monoclonal antibody agents and combination therapy strategies. Clinical use is challenging due to dose limiting side effects and severe anemia. Better understanding of the whole-body dynamics of CD47/SIRPα can be used to improve the developmental and therapeutic strategies targeting this axis. Herein, we developed anti-CD47 and anti-SIRPα radiotracers with good yields and stability. CD47/SIRPα biodistribution showed consistent whole-body results in healthy and colorectal cancer (CT26) allograft mice, demonstrating significant uptake in normal organs liver and spleen in addition to tumor accumulation of these agents. Enhancing immunogenicity via low-dose radiotherapy had no impact on over-all biodistribution but caused small, significant changes for anti-SIRPα tumor uptake. Antibody PEGylation of the anti-SIRPα tracer was further able to modify the whole-body distribution and reduce splenic uptake. These findings suggest that SIRPα targeted agents may benefit from co-therapies and drug delivery systems to optimize tumor uptake. Our work highlights the importance of in vivo molecular imaging in addition to in vitro and ex vivo assays when evaluating therapeutic designs.
- Open Access
- 23 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (21) , eadv2930
Image-guided targeting of mitochondrial metabolism sensitizes pediatric malignant rhabdoid tumors to low-dose radiotherapy
Tumor hypoxia leads to radioresistance and markedly worse clinical outcomes for pediatric malignant rhabdoid tumors (MRTs). Our transcriptomics and bioenergetic profiling data reveal that mitochondrial oxidative phosphorylation is a metabolic vulnerability of MRT and can be exploited to overcome consumptive hypoxia by repurposing an FDA-approved antimalarial drug, atovaquone (AVO). We then establish the utility of oxygen-enhanced-multispectral optoacoustic tomography, a label-free, ionizing radiation-free imaging modality, to visualize and quantify spatiotemporal changes in tumor hypoxia in response to AVO. We show a potent but transient increase in tumor oxygenation upon AVO treatment that results in complete elimination of tumors in all tested mice when combined with 10-gray radiotherapy, a dose several times lower than the current clinic standard. Last, we use translational mathematical modeling for systematic evaluation of dosing regimens, administration timing, and therapeutic synergy in a virtual patient cohort. Together, our work establishes a framework for safe and pediatric patient-friendly image-guided metabolic radiosensitization of rhabdoid tumors.
- 23 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (21) , eadv2930
Open AccessImage-guided targeting of mitochondrial metabolism sensitizes pediatric malignant rhabdoid tumors to low-dose radiotherapy
Tumor hypoxia leads to radioresistance and markedly worse clinical outcomes for pediatric malignant rhabdoid tumors (MRTs). Our transcriptomics and bioenergetic profiling data reveal that mitochondrial oxidative phosphorylation is a metabolic vulnerability of MRT and can be exploited to overcome consumptive hypoxia by repurposing an FDA-approved antimalarial drug, atovaquone (AVO). We then establish the utility of oxygen-enhanced-multispectral optoacoustic tomography, a label-free, ionizing radiation-free imaging modality, to visualize and quantify spatiotemporal changes in tumor hypoxia in response to AVO. We show a potent but transient increase in tumor oxygenation upon AVO treatment that results in complete elimination of tumors in all tested mice when combined with 10-gray radiotherapy, a dose several times lower than the current clinic standard. Last, we use translational mathematical modeling for systematic evaluation of dosing regimens, administration timing, and therapeutic synergy in a virtual patient cohort. Together, our work establishes a framework for safe and pediatric patient-friendly image-guided metabolic radiosensitization of rhabdoid tumors.